Modulating effects of WT1 on interferon-β-vitamin D association in MS

Acta Neurologica Scandinavica

Volumn 131, Issue 4, 2015, Pages 231-239

  Lin, R ^a,b   Taylor, B V ^a   Charlesworth, J ^a   van der Mei, I ^a   Blizzard, L ^a   Stewart, N ^c,d   Ponsonby, A L ^e   Dwyer, T ^e   Pittas, F ^d   Simpson, Jr ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b GUANGXI CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c UNIVERSITY OF TASMANIA   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

Genetic; Interferon ; Multiple sclerosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; WT1 PROTEIN; 25-HYDROXYVITAMIN D; IMMUNOLOGIC FACTOR; VITAMIN D;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDY; RELAPSE; RISK FACTOR; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; SUN EXPOSURE; SURVIVAL; ANALOGS AND DERIVATIVES; BLOOD; GENETICS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE; SUNLIGHT; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADULT; AGED; COHORT STUDIES; FEMALE; GENES, WILMS TUMOR; GENOTYPE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECURRENCE; SUNLIGHT; VITAMIN D; YOUNG ADULT;

EID: 84925149340     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12315     Document Type: Article

References (30)

1. Prisms Study Group and the University of British. Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36.
2. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-53.
3. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology 2007;68:S8-11.
4. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-9.
5. Stewart N, Simpson Jr. S, van der Mei I, Ponsonby AL et al. Interferon-beta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012;79:254-60.
6. CANTOR F, OHAYON J, RICHERT N, et al. Vitamin D, sunlight and multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England) 2011; 17: S307.
7. Simpson SL Jr, Taylor B, Blizzard L et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS. Annal Neurol 2010;68:193-203.
8. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9:599-612.
9. Runia TF, Hop WC, de Rijke YB, Buljevac D, Hintzen RQ. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79:261-6.
10. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-8.
11. Mowry E, Krupp L, Milazzo M et al. Vitamin D status is associated with relapse rate in pediatric-onset MS. Annal Neurol 2010;67:618-24.
12. Wang TJ, Zhang F, Richards JB et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010;376:180-8.
13. The Australia and New Zealand Multiple Sclerosis Genetics. Consortium (Anzgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009;41:824-8.
14. Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-9.
15. Simon KC, Munger KL, Xing Y, Ascherio A. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult Scler 2010;16:133-8.
16. Dickinson JL, Perera DI, van der Mei AF et al. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Mult Scler 2009;15:563-70.
17. Lin R, TAYLOR BV, SIMPSON S, JR ., et al. Novel modulating effects of PKC family genes on the relationship between serum vitamin D and relapse in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 85: 399-404.
18. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002;22:139-66.
19. Vidal M, Ramana CV, Dusso AS. Stat1-vitamin D receptor interactions antagonize 1, 25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol 2002;22:2777-87.
20. Pittas F, Ponsonby AL, van der Mei IA et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 2009;256:577-85.
21. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
22. Konradsen S, Ag H, Lindberg F, Hexeberg S, Jorde R. Serum 1, 25-dihydroxy vitamin D is inversely associated with body mass index. Eur J Nutr 2008;47:87-91.
23. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Human Gen 2007;81:559-75.
24. Clarke L, Zheng-Bradley X, Smith R et al. The 1000 Genomes Project: data management and community access. Nat Methods 2012;9:459-62.
25. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008;24:2938-9.
26. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika 1981;68:373-9.
27. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004;74:765-9.
28. Maurer U, Jehan F, Englert C et al. The Wilms' tumor gene product (WT1) modulates the response to 1, 25-dihydroxyvitamin D3 by induction of the vitamin D receptor. J Biol Chem 2001;276:3727-32.
29. Lee TH, Pelletier J. Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter. Physiol Genomics 2001;7:187-200.
30. Loken-Amsrud KI, Holmoy T, Bakke SJ et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-beta treatment. Neurology 2012;79:267-73.